SAN DIEGO -- Inebilizumab (Uplizna) improved function and reduced disease severity for up to 52 weeks in generalized myasthenia gravis (gMG) patients who were acetylcholine receptor (AChR ...

The FDA is reviewing a request for approval of FcRn blocker nipocalimab in generalized myasthenia gravis (gMG). J&J is late to the party, with argenx and UCB already selling rival FcRn blockers ...

presented “The Path to Diagnosis and Treatment Among Patients With Generalized Myasthenia Gravis (gMG): Health Disparities Experienced by Racial and Ethnic Minorities From Project ASPIRE ...